Fischer Christine, Hofmann Rainer, Hegele Axel
Department of Urology and Pediatric Urology, University Medical Center, Marburg, Germany.
Cancer Manag Res. 2020 Jun 26;12:5077-5084. doi: 10.2147/CMAR.S231508. eCollection 2020.
BACKGROUND/AIM: Up to 30% of all patients will present with an advanced or a metastatic stage (mUCC) at the moment of the initial diagnosis of urothelial cell carcinoma of the bladder (UCC). We investigated the numbers, the efficacy and toxicity of different chemotherapies for mUCC in daily practice and "real-life" conditions and evaluated them substance-specifically.
All patients with a mUCC, who were treated between January 1, 2006 and October 31, 2016 at the Department of Urology and Pediatric Urology at University Hospital Marburg (Germany), were retrospectively analyzed. We set the focus on demographic and tumor-specific data as well as on effectiveness, therapy sequences, and drug tolerance.
Forty-one patients were identified. Of the 41 patients, 85.4% of the patients in first-line therapy received gemcitabine/cisplatin. A large proportion of 85.4% received a second-line therapy and 40% a third-line therapy due to progress or relapse. Median overall survival (mOS) was 18 months including all patients and increased up to 29.5 months in the cases of three therapy lines.
Our data reveal that chemotherapy of mUCC is effective and side effects are manageable in daily clinical practice.
背景/目的：在膀胱癌（UCC）初次诊断时，高达30%的患者会出现晚期或转移性阶段（mUCC）。我们在日常实践和“现实生活”条件下研究了不同化疗方案治疗mUCC的数量、疗效和毒性，并对其进行了特定药物评估。
对2006年1月1日至2016年10月31日期间在德国马尔堡大学医院泌尿外科和小儿泌尿外科接受治疗的所有mUCC患者进行回顾性分析。我们重点关注人口统计学和肿瘤特异性数据，以及疗效、治疗顺序和药物耐受性。
共确定41例患者。在41例患者中，一线治疗的患者中有85.4%接受了吉西他滨/顺铂治疗。由于疾病进展或复发，85.4%的患者接受了二线治疗，40%的患者接受了三线治疗。所有患者的中位总生存期（mOS）为18个月，在接受三线治疗的患者中，mOS延长至29.5个月。
我们的数据表明，在日常临床实践中，mUCC化疗有效且副作用可控。
